spacer
home > news > detailed info
INDUSTRY NEWS AND PRESS RELEASES

Horizon Discovery Licenses Biomanufacturing Cell Lines to Centre for Process Innovation (CPI) and National Institute for Bioprocessing Research and Training (NIBRT)

Horizon Discovery Group

World leader in gene editing technology announces establishment of two new partnerships

  • Horizon helps CPI and NIBRT improve biomanufacturing through provision of novel bioproduction cell lines
  • Post programme, Horizon will seek to continue to support companies working with CPI and NIBRT
Cambridge, UK, 13 September 2016: Horizon Discovery Group plc (LSE: HZD) ("Horizon"), the world leader in the application of gene editing technologies, today announces the establishment of new partnerships with both the Centre for Process Innovation (CPI) and the National Institute for Bioprocessing Research and Training (NIBRT) to support biologic therapeutic manufacturing in the UK, Ireland and beyond.

Biological therapeutics represented seven of the top ten best selling drugs of 2015, and they feature extensively in developmental pipelines. Access to bioproduction cell lines for their manufacture can be cost prohibitive, and is often restricted in ways that prevent their further optimisation by customers. This stifles innovation and can impede the launch of biological therapeutics due to the challenge of generating bioproduction cell lines that meet the needs of commercial release.

Horizon is using its expertise in genome engineering to improve biological therapeutics manufacturing. As well as developing a tool box of cell lines for the manufacture of a range of current and next generation biological therapeutics, Horizon aims to encourage innovation in other organisations by allowing access to its state of the art bioproduction cell line platform (CHO SOURCE) under flexible licensing terms that include allowing the further modification of cells. This agreement allows any organisation, through CPI or NIBRT, to access Horizon’s state of the art biomanufacturing cell lines for research purposes, benefiting the global bioprocessing community by allowing access to cutting edge bioproduction cell lines at an early stage of drug or technology development. This initiative reinforces Horizon’s reputation as a leader and innovator, well positioned to support new biomanufacturing programmes whether in the UK or globally. Upon completion of these studies, it is anticipated that many organisations will continue to use Horizon’s cell lines, thereby establishing a long-term revenue stream for these high value products as they transition to use for commercial manufacture.

Darrin Disley, CEO, Horizon Discovery, commented:“Horizon is committed to driving innovation in bioprocessing. We value the opportunity to work with key industry players including CPI and NIBRT, to ensure that we are delivering the best solutions for our customers and ultimately for patients.”

Fergal O’Brien, Director of Biologics, CPI said: “By providing their cell line for our research use, Horizon, together with the expertise of CPI, will create a powerhouse platform to develop bioprocessing solutions. We’re excited to see the impact that this programme will have.”

Killian O’Driscoll, Director of Projects, NIBRT said: “NIBRT are delighted to interact with Horizon, to combine their excellence and know-how in cell line development with NIBRT’s cutting edge research, which together will provide solutions of real impact for the advancement and improvement of biopharmaceutical manufacturing.”
phone +44 (0)1223 655 580
web www.horizondiscovery.com/
email 7100 Cambridge Research Park, Waterbeach, Cambridge, CB25 9TL
 
Print this page
Send to a friend
   
spacer
News and Press Releases

Teknomek’s latest seating bench steps up, and over

Teknomek’s long-serving free-standing stainless steel seating bench has been updated with a raft of design tweaks to make it even more hygienic, easy clean and ergonomic.
More info >>


White Papers

Bringing more control to temperature-sensitive logistics

UPS Supply Chain Solutions

By 2016, world sales of cold-chain drugs and biologics such as vaccines and blood plasma products will near $240 billion1. The increase has led to a surge in discussion about how to protect these products throughout the transportation logistics cycle. Industry experts are recommending that the term “cold chain” be eliminated from rules, guidance and best-practice documents. “Cold chain” now includes a broader spectrum of temperature ranges, such as controlled room temperature (CRT). This white paper focuses on the initial steps required to establish a temperature-sensitive supply chain.
More info >>

Industry Events

SAPHEX 2018

1-2 November 2018, Gallagher Convention Centre, Midrand, South Africa

The SAPHEX exhibition and conference is now established as the “go-to” networking and business event for anyone working in the South African pharmaceutical manufacturing industry.
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement